Orange Biotech Limited

Company Overview:
Orange Biotech, based in Hong Kong, is a pioneering enterprise specialising in exclusive CRISPR technology and microfluidics. Our primary objective is to make medical-grade nucleic acid testing as an daily necessity. In collaboration with HKUST Business School, our research highlights a surge in demand for self-testing products post the widespread adoption of COVID-19 rapid antigen tests (RAT). With the Chinese IVD market poised to reach 190 billion RMB by 2028, Orange Biotech is strategically positioned to cater to this escalating need by offering heightened sensitivity, competing directly with RAT solutions.
Technology and Product:
Our flagship product, DetectChip, merges PCR sensitivity with RAT's user-friendly operation, enabling convenient at-home nucleic acid testing. Leveraging CRISPR technology and microfluidic chips, DetectChip provides sensitive and multiplexed detection for respiratory infections, STDs, and various health issues. We have secured four U.S. patents for our CRISPR-based nucleic acid diagnostic innovations. With successful validation on clinical HPVs and COVID-19 samples, our urine and respiratory swab test pipelines are being fine-tuned for imminent production. Additionally, we plan to launch non-medical products for pets and agriculture, optimising manufacturing efficiency and quality control in collaboration with partners.
Current Sales and Business Model:
As a CRISPR-based diagnostics company, we have effectively distributed our solutions, including assays, enzymes, and designs, to regional entities and hospitals since December. Our business model hinges on partnerships with established firms for conventional channel sales and targets e-commerce avenues to reach clinics and individuals. Collaborations with industry stalwarts like Lepu Medical and Thunderbio involve funding applications, product co-developments, and technology sub-licensing.
Team Introduction:
Our core team members boast extensive R&D proficiency in microfluidics-based CRISPR-based nucleic acid detection, accumulating over seven years of experience in the domain. Their backgrounds encompass varied roles in research, startups, and industry across Asia and Europe. Notably, our co-founder has secured over 200 million RMB in investment for a separate microfluidics venture. Supported by a network of adept advisors and consultants in CRISPR diagnostics, clinical trials, regulatory affairs, patent management, and marketing, our team is well-equipped to drive Orange Biotech's success.
In essence, Orange Biotech stands at the forefront of the self-testing revolution, endeavoring to provide individuals with heightened sensitivity in nucleic acid testing through easy-to-operate products. Backed by our innovative DetectChip solution, a robust IP portfolio, strategic alliances, and a highly skilled team, we are primed to meet the escalating demand for convenient, sensitive, and multiplexed at-home testing solutions.

Orange Biotech, established in 2022 in Hong Kong, is a startup reagent company specialising in CRISPR technology and microfluidics. Our expert team from institutions like HKUST and Oxford, is dedicated to developing innovative nucleic acid detection solutions for disease prevention and screening.

We offer integrated Point of Care Testing (POCT) products for home-based testing, focusing on disease confirmation, prevention, and post-treatment re-examination. Our mission includes bringing nucleic acid tests to the general public, akin to rapid antigen tests, with a focus on low cost, multiplexed diagnostics, and easy operation. Our goal is to make nucleic acid testing accessible and affordable for early disease detection and management, empowering individuals to prioritise their health.